WO2015141926A1 - Composition pour inhiber ou atténuer un vieillissement cutané causé par une stimulation de stress, contenant de la trapa japonica comme principe actif - Google Patents

Composition pour inhiber ou atténuer un vieillissement cutané causé par une stimulation de stress, contenant de la trapa japonica comme principe actif Download PDF

Info

Publication number
WO2015141926A1
WO2015141926A1 PCT/KR2014/011418 KR2014011418W WO2015141926A1 WO 2015141926 A1 WO2015141926 A1 WO 2015141926A1 KR 2014011418 W KR2014011418 W KR 2014011418W WO 2015141926 A1 WO2015141926 A1 WO 2015141926A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
skin
extract
fraction
lotion
Prior art date
Application number
PCT/KR2014/011418
Other languages
English (en)
Korean (ko)
Inventor
남진주
노윤화
염종경
김한곤
Original Assignee
코스맥스 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코스맥스 주식회사 filed Critical 코스맥스 주식회사
Publication of WO2015141926A1 publication Critical patent/WO2015141926A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof

Definitions

  • composition for inhibiting or improving skin aging due to stress stimulation containing twill extract as an active ingredient
  • the present invention is made by the task number HN12C0061 in support of the Ministry of Health and Welfare, the research management professional organization of the task is a global cosmetic research and development project,
  • the present invention relates to a composition for inhibiting or improving skin aging due to stress stimulation containing a twill extract as an active ingredient, and more specifically for inhibiting or improving skin aging due to stress stimulation containing a twill extract or a twill fraction as an active ingredient. It relates to a cosmetic composition or a topical skin composition.
  • Aging refers to the gradual decline in physiological function of normal function as a result of complex human mechanisms.
  • the skin contains keratinocytes, melanocytes, islets of Langerhans, fibroblasts and adipocytes. These cells undergo aging and change in physiological function, shape, and structure.
  • Skin aging is divided into two types: intr ic aging and photoaging. Endogenous aging is irrelevant to the external environment with the passage of time. It refers to the aging phenomenon that occurs naturally depending on the genetic factors. On the other hand, photoaging is a phenomenon caused by external environmental factors and can be avoided because it can be artificially controlled. The representative factor of photoaging is ultraviolet light, which leads to the activation of proteolytic enzymes, chain breakage of substrate proteins and damage of biological components of abnormal cross-links, and repetition of this mechanism leads to apparent skin aging. .
  • Wrinkles, decreased skin elasticity, sagging and dryness in aged skin are mostly due to changes in matrix proteins present in the dermis.
  • the dermis is located directly below the epidermis and determines the strength and shape of the skin. Therefore, when aging progresses, morphological changes occur in this area, which leads to a change in elasticity.
  • Ps Moatr ix metal loproteinases
  • ⁇ P activity is increased in the skin even with a single UV irradiation, and it significantly degrades collagen and other substrate proteins in the skin to promote skin aging. It acts as a major factor.
  • Intracellular reactions by stress are reactions of glucocorticoids acting as stress hormones and are regulated by secretion of active cortisol and ⁇ ⁇ -HSDl (11 ⁇ -hydroxysteroid dehydrogenasel) activity.
  • ⁇ ⁇ -HSDl converts inactive glucocorticoids into active glucocorticoids, thereby playing an important role in regulating the concentration of cellular agents and activating corticosteroid receptors in target tissues.
  • ⁇ ⁇ -HSDl converts inactive glucocorticoids into active glucocorticoids, thereby playing an important role in regulating the concentration of cellular agents and activating corticosteroid receptors in target tissues.
  • the present inventors have made diligent research efforts to overcome the problems of the prior art, to discover that the role of ⁇ -HSDl activated by ultraviolet light is related to photoaging and to find a substance that improves the efficacy of anti-aging Based on the plant extracts reported to have been compared and selected, among them, the extracts of the filth extract or its fractions, ⁇ ⁇ -HSDl and ⁇ Ps, the expression of inflammatory factors and the thickness of the dermis . It has been confirmed that the inhibition of skin aging, the improvement and treatment of aging skin can be suppressed, and the present invention has been completed.
  • the main object of the present invention is to inhibit the skin aging by inhibiting the expression of ⁇ -HSDl and ⁇ Ps, the expression of inflammatory factors and the thickness of the dermis, which has the effect of improving the aging skin. It is to provide a composition for inhibiting or improving skin aging due to stress stimulation containing a twill extract or a twill fraction as an active ingredient.
  • Another object of the present invention is to provide a method for use in the preparation of a composition for inhibiting or improving skin aging due to stress stimulation of the stalk extract or stalk fraction or a method for inhibiting or improving skin aging using such a composition.
  • the present invention provides a composition for inhibiting or improving skin aging due to stress stimulation, which contains an extract of the stalk extract or the stalk fraction as an active ingredient.
  • the composition is characterized in that it is used as a cosmetic or skin external preparation.
  • Thunsil is a yearly grass that grows in water and has elongated stems. Each node floats in the shape of a feather-shaped water root. This insufficiency is effective in nourishing and tonic, so the body is a good nutritional to the weak, it is known to detoxify and act as a detoxification.
  • Korean Patent No. 10-0927970 discloses that the extract of twill is effective in inhibiting sebum secretion and acne.
  • the present inventors have found that the twill extract has an effect of suppressing skin photoaging due to stress stimulation, in particular, stress stimulation by ultraviolet rays, and thus, the present invention has been completed.
  • the term 'stress stimulus' of the present invention means that harmful stimuli from the external environment increase the stress hormone (glucocorticoid) in the skin and cause skin aging or skin atrophy. In the present invention, it means specifically by stress stimulation by ultraviolet rays.
  • the skin aging may be photoaging by ultraviolet rays, moreover.
  • it is characterized by photoaging by UVB Jl travi olet B).
  • the term 'photo-aging (Phhtoagipg)' of the present invention is a phenomenon caused by external environmental factors, and the most representative factor is ultraviolet rays. This ultraviolet light causes damage to biological components such as protease activation, substrate protein chain breakdown and abnormal crosslinking, and the repetition of this mechanism leads to apparent skin aging. That is, in the present invention, unlike endogenous aging caused by genetic factors regardless of the external environment, a composition for inhibiting or improving skin aging caused by photoaging caused by ultraviolet rays, in particular a cosmetic composition, or It relates to an external preparation composition for skin.
  • the twill extract can be extracted with any solvent conventionally used .
  • water, lower alcohol having 1 to 4 carbon atoms, polyhydric alcohol having 3 to 6 carbon atoms, glycerin, propylene glycol or butylene glycol is characterized in that the extraction with one or more solvents selected from the group consisting of.
  • the lysyl fraction can be fractionated by any solvent used in the conventional systematic fractionation method, preferably a low polar organic solvent, more preferably nucleic acid, methylene chloride, ethyl acetate or n -Fractionate with at least one solvent selected from the group consisting of butanol.
  • a low polar organic solvent more preferably nucleic acid, methylene chloride, ethyl acetate or n -Fractionate with at least one solvent selected from the group consisting of butanol.
  • the twill extract or the twill fraction may be used as it is, characterized in that it can be used in the form of a concentrated lyophilized or lyophilized after filtration.
  • the skin aging is 11 beta-HSD 1 (11 ⁇ _ It is characterized by inhibiting or improving skin aging by inhibiting the expression of hydroxysteroid dehydrogenasel).
  • 11beta-HSD1 (11 ⁇ -hydroxysteroid dehydrogenasel, ⁇ -HSDl) regulates the reaction of glucocorticoids to act as stress hormones.
  • ⁇ -HSDl increases Î ⁇ -HSDl activity in the skin with age (Tiganescu A et al, 2013; 123 (7): 3051-3060).
  • the researchers found that the activity of ⁇ -HSDl at the site where photoaging occurred was about 4 times higher than the site where endogenous aging occurred. Reported (Tiganescu A et al, 2011; 131, 30-36).
  • the skin aging is characterized by inhibiting or improving skin aging by inhibiting the expression of ⁇ Ps and inflammatory factors.
  • ⁇ Ps (Matrix metal loproteinases) is increased ⁇ P activity in the skin in a single UV irradiation Representative enzymes that break down matrix proteins and i to to significantly decompose collagen and other matrix proteins in the skin, it promotes skin aging increases important factor Acts as.
  • the skin aging is characterized in that to suppress or improve the skin aging by inhibiting the reduction of the dermal layer thickness.
  • the twill extract or the twill fraction is characterized in that it comprises 0.01 to 90% by weight relative to the total weight of the composition. If it is outside the above range, the formulation is not easy and is not preferable.
  • the composition may be prepared in any formulation commonly prepared in the art, for example, emulsion, cream, lotion, pack, foundation, lotion, essence, hair cosmetics, etc. .
  • Cosmetic compositions of the present invention may include other auxiliaries in addition to the carrier, for example, may include preservatives, antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors.
  • the composition may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, and other external preparations and sterile injectable solutions, respectively, according to a conventional method. May have a cream, gel, patch, spray, ointment, warning, lotion, liniment pasta or cataplasma formulation.
  • Carriers, excipients, and diluents that may be included in the composition include lactose, dextrose, sucrose, oligosaccharides, sorbbi, manny, xili, and erythritol. Malty, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, Talc, magnesium stearate and mineral oil.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants are usually used.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like. Such solid preparations may contain at least one excipient such as starch, calcium carbonate, water, or the like. Prepared with a mixture of sucrose or lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspending agents, liquid solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
  • base of the suppository wi tepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the preferred dosage of the composition also depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the composition of the present invention is preferably administered at 0.0001 to 100mg / kg, preferably 0.001 to 10mg / kg per day. Topical administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • the filth extract or fraction extract of the present invention inhibits the expression of ⁇ ⁇ -HSDl, MMPs and inflammatory factors overexpressed by UV light.
  • the filth extract or fraction extract of the present invention inhibits the expression of ⁇ ⁇ -HSDl, MMPs and inflammatory factors overexpressed by UV light.
  • Figure 1 is a picture of the results of Experimental Example 1 measuring the effect on the expression of ⁇ ⁇ -HSDl protein 'in the treatment of the extract and fractions in human fibroblasts.
  • Figure 2 is a graph of the results of Experimental Example 2 measuring the effect on the P-1 protein expression in the treatment of the extract and fractions in human fibroblasts.
  • Figure 3 is a graph of the results of Experimental Example 3 measuring the effect on ⁇ P-3 messenger RNA expression in the treatment of the extract and fractions in human fibroblasts.
  • FIG. 4 is a graph showing the results of Experimental Example 3, which measured the effect of fflP-9 messenger R A expression upon treatment of filth extract and fraction on human fibroblasts.
  • Figure 5 is a graph of the results of Experimental Example 4 measuring the effect on the C0X-2 messenger RNA expression when treatment with the extract and fractions in human keratinocytes.
  • Figure 6 is a graph of the results of Experimental Example 4 measuring the effect on the expression of iNOS messenger R A in the treatment of extracts and fractions in human keratinocytes.
  • Figure 7 is a graph of the results of Experimental Example 5 measuring the effect on the P-1 protein expression in the treatment of the extract and fractions in the three-dimensional artificial skin.
  • Figure 8 is a graph of the results of Experimental Example 6 measuring the effect on the change in the thickness of the dermis layer during the treatment of the sample containing the twill extract in the photo-aging skin animal model.
  • Tungsil used in the present invention was purchased from the herbal medicine of Gyeongdong market, Seoul, Korea.
  • Electrophoresis using SDS-PAGE Sod i umdodecy 1 su 1 f at e-po 1 yacry 1 am i de gel electrophoresis
  • transfer protein bands to PVDF Polyvinyl idene fluoride, Bio-rad, USA
  • Enhanced chemi luminescence, ThermoScient if ic, USA was confirmed the amount of protein expression.
  • RT-PCR was performed using a PCR machine (Step One Plus, Applied Biosystems, USA) and assayed by the addition of cyberrin (SYBRGreen supermix, Applied Biosystems, USA) with P-3 and P-9 primers and cDNA.
  • the primer and reaction conditions were shown in Table 1 below, and the expression levels of ⁇ P-3 and ⁇ P-9 were expressed by correcting the ⁇ -actin gene.
  • Human keratinocytes were cultured in the same manner as described in Experimental Example 3 above, the cells were inoculated into 6 we ll plates and irradiated with UVB 15mJ after 24 hours, and then each extract was added. After further incubation for 24 hours, real-t ime RT-PCR was carried out in the same manner as in Experiment 2 to measure messenger RNA expression levels of inflammatory factors C0X-2 ( C yc looxygenase_2) and iNOS (inducibl e NO synthase).
  • C0X-2 C yc looxygenase_2
  • iNOS inducibl e NO synthase
  • Example 5 MMP-1 Inhibitory Activity of Twill Extract in Three-Dimensional Skin Tissues
  • P-1 expression of the twill extract of Example 1 was confirmed using three-dimensional artificial skin tissue.
  • Epi dermal ti ssue (Skin Ethi cs, Nikoderm Research Inc., France) was stabilized in growth medi a for 24 hours, and then irradiated with UVB 40mJ. Enzyme-linked immunosorbent assay (enzyme- l inked) to quantify the amount of protein secretion of ⁇ P-1 after incubation for 72 hours An immunosorbent assay (ELISA) was performed.
  • the effect of the sample containing the twill extract of Example 1 on the photoaging skin animal model was evaluated. Dermal mice were irradiated with ultraviolet rays three times a week for a total of eight weeks, and the samples containing the twill methanol extract were mixed with the base and applied twice a day for a total of eight weeks to measure dermal thickness.
  • the base was mixed with PG (propylene glycol): EtOH (ethane) at 7: 3 and treated with sham light to serve as a control.
  • the toner agent containing the extract obtained in Example 1 was prepared in a conventional manner according to the composition components and composition ratios shown in Table 2 below.
  • the cream containing the extract obtained in Example 1 was prepared in a conventional manner according to the composition components and composition ratios shown below.
  • Example 1 ⁇ 1 1.0 Glyceryl Stearate / Sebum -1 00 Stearate 2.0 Fully Solate 60 0.5

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition cosmétique ou une composition de préparation cutanée à usage externe pour inhiber ou atténuer un vieillissement cutané causé par une stimulation de stress, contenant un extrait deTrapa japonica ou une fraction de Trapa japonica comme principe actif. Selon la présente invention, l'extrait de Trapa japonica ou une fraction de celui-ci peut inhiber un vieillissement cutané, et atténuer et traiter le vieillissement cutané par l'inhibition de 11β-HSD1 et MMP, de l'expression de facteurs d'inflammation et de la diminution de l'épaisseur du derme.
PCT/KR2014/011418 2014-03-17 2014-11-26 Composition pour inhiber ou atténuer un vieillissement cutané causé par une stimulation de stress, contenant de la trapa japonica comme principe actif WO2015141926A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140030820A KR20150108088A (ko) 2014-03-17 2014-03-17 능실 추출물을 유효성분으로 함유하는 스트레스 자극에 의한 피부노화 억제 또는 개선용 조성물
KR10-2014-0030820 2014-03-17

Publications (1)

Publication Number Publication Date
WO2015141926A1 true WO2015141926A1 (fr) 2015-09-24

Family

ID=54144856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2014/011418 WO2015141926A1 (fr) 2014-03-17 2014-11-26 Composition pour inhiber ou atténuer un vieillissement cutané causé par une stimulation de stress, contenant de la trapa japonica comme principe actif

Country Status (2)

Country Link
KR (1) KR20150108088A (fr)
WO (1) WO2015141926A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109431846A (zh) * 2018-11-28 2019-03-08 邯郸学院 一种生物活性成分护肤品
CN115485338A (zh) * 2020-05-04 2022-12-16 Omya国际股份公司 化学和物理防晒用干组合物和/或乳液及其用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102344703B1 (ko) * 2018-12-28 2021-12-30 에이앤펩주식회사 마름 발효물의 제조방법과 이로부터 제조된 마름 발효물이나 펩타이드를 유효성분으로 함유하는 피부 주름 개선, 항노화에 효과가 있는 조성물과 발효물로 이루어진 피부노화 개선용 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100706282B1 (ko) * 2004-05-13 2007-04-11 학교법인 인제학원 항산화 활성을 갖는 마름 추출물을 포함하는 조성물
KR100927970B1 (ko) * 2007-10-31 2009-11-24 주식회사 코리아나화장품 능실 추출물을 유효성분으로 함유하는 피지 분비 억제 및여드름 완화용 화장료 조성물
WO2011126295A2 (fr) * 2010-04-06 2011-10-13 (주)아모레퍼시픽 Procédé de fermentation par emballage dans des feuilles médicinales et composition pour préparation cutanée à usage externe ainsi obtenue
KR101116757B1 (ko) * 2009-01-23 2012-03-13 한국과학기술연구원 능실로부터 분리된 신규 화합물 및 이를 함유하는 항산화 조성물
JP2014037399A (ja) * 2012-07-18 2014-02-27 Up Well:Kk 抗糖化剤およびその製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100706282B1 (ko) * 2004-05-13 2007-04-11 학교법인 인제학원 항산화 활성을 갖는 마름 추출물을 포함하는 조성물
KR100927970B1 (ko) * 2007-10-31 2009-11-24 주식회사 코리아나화장품 능실 추출물을 유효성분으로 함유하는 피지 분비 억제 및여드름 완화용 화장료 조성물
KR101116757B1 (ko) * 2009-01-23 2012-03-13 한국과학기술연구원 능실로부터 분리된 신규 화합물 및 이를 함유하는 항산화 조성물
WO2011126295A2 (fr) * 2010-04-06 2011-10-13 (주)아모레퍼시픽 Procédé de fermentation par emballage dans des feuilles médicinales et composition pour préparation cutanée à usage externe ainsi obtenue
JP2014037399A (ja) * 2012-07-18 2014-02-27 Up Well:Kk 抗糖化剤およびその製造方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109431846A (zh) * 2018-11-28 2019-03-08 邯郸学院 一种生物活性成分护肤品
CN109431846B (zh) * 2018-11-28 2021-09-07 邯郸学院 一种生物活性成分护肤品
CN115485338A (zh) * 2020-05-04 2022-12-16 Omya国际股份公司 化学和物理防晒用干组合物和/或乳液及其用途

Also Published As

Publication number Publication date
KR20150108088A (ko) 2015-09-25

Similar Documents

Publication Publication Date Title
US10849840B2 (en) Compositions and methods for stimulation MAGP-1 to improve the appearance of skin
KR102126469B1 (ko) 철피석곡 꽃 추출물을 포함하는 화장료 조성물
US7642062B2 (en) Compositions and methods of their use for improving the condition and appearance of skin
TW201206494A (en) Use of Tiliacora triandra in cosmetics and compositions thereof
CN103379910A (zh) 白花菜地上部分提取物及包含其的化妆品、皮肤病学或药物组合物
CN113874044B (zh) 皮肤组合物
TWI423810B (zh) 舞茸萃取物及含有其的用於促進玻尿酸產生的組成物
WO2015141926A1 (fr) Composition pour inhiber ou atténuer un vieillissement cutané causé par une stimulation de stress, contenant de la trapa japonica comme principe actif
JP2020502172A (ja) 漢方薬抽出物を有効成分として含む化粧料組成物
JP6338107B2 (ja) 皮膚バリア機能改善剤、細胞間接着構造の形成促進剤、タイトジャンクション形成促進剤及びｔｒｐｖ４遺伝子の発現亢進剤
KR102612128B1 (ko) 조팝나무 추출물을 유효성분으로 함유하는 탈모방지 및 모발 성장용 조성물
JP2009235044A (ja) エンドセリン−１ｍＲＮＡ発現抑制剤、マトリックスメタロプロテアーゼ−９ｍＲＮＡ発現抑制剤、コラーゲン産生促進剤、プロフィラグリン産生促進剤、フィラグリン産生促進剤及びアクアポリン３ｍＲＮＡ発現促進剤
KR20100056200A (ko) 사삼, 고본 및 생약 추출물을 포함하는 것을 특징으로 하는화장료 조성물
JP2011102264A (ja) アロマターゼ活性化剤
KR102124698B1 (ko) 국화, 알로에, 서양송악 혼합 추출물을 유효성분으로 함유하는 피부 노화 또는 피부 주름 개선용 화장료 조성물
KR101702621B1 (ko) 꽃잔디 추출물을 포함하는 항염증제
KR20140013791A (ko) 진세노사이드 Ｒｈ2 및 진세노사이드 Ｒｇ3를 함유하는 기능성 화장료 조성물
JP2012219031A (ja) ラミニン５産生促進剤、インテグリンα６β４産生促進剤、皮膚基底膜正常化剤、皮膚損傷回復促進剤及びアクアポリン３ｍＲＮＡ発現促進剤
KR102114682B1 (ko) 진세노사이드 Rg3, Rg5 및 Rk1을 함유하는 주름 개선용 화장료
KR20210131680A (ko) 펙틴을 포함하는 탈모 방지 또는 발모 촉진용 조성물
EP3300738A1 (fr) Composition pour le traitement des plaies contenant un extrait de parts aériens de stellara chamaejasme
JP6017259B2 (ja) エンドセリン作用抑制剤
WO2017057929A1 (fr) Composition cosmétique pour la prévention du vieillissement de la peau et l'atténuation des rides contenant un extrait de mélange de fruits de rosa multiflora thunberg et de graines de kochia scoparia schrader
KR101715590B1 (ko) 11β-히드록시스테로이드 디하이드로게나제 타입 1의 활성을 저해하는 화합물을 포함하는 피부 노화 방지용 화장료 조성물 또는 피부 외용제 조성물
KR101784894B1 (ko) 피부노화 개선 활성을 가지는 우이초 추출물의 향장 또는 약학적 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14886575

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14886575

Country of ref document: EP

Kind code of ref document: A1